Novel anti-TM4SF1 antibody-drug conjugates with activity against tumor cells and tumor vasculature

Molecular Cancer Therapeutics

Volumn 14, Issue 8, 2015, Pages 1858-1876

  Visintin, Alberto ^a   Knowlton, Kelly ^a   Tyminski, Edyta ^a   Lin, Chi Iou ^b   Zheng, Xiang ^a   Marquette, Kimberly ^a   Jain, Sadhana ^a   Tchistiakova, Lioudmila ^a   Li, Dan ^b   O'Donnell, Christopher J ^a   Maderna, Andreas ^a   Cao, Xianjun ^a   Dunn, Robert ^a   Snyder, William B ^a   Abraham, Anson K ^a   Leal, Mauricio ^a   Shetty, Shoba ^a   Barry, Anthony ^a   Zawel, Leigh ^a   Coyle, Anthony J ^a   Dvorak, Harold F ^b   Jaminet, Shou Ching ^b   more..

^a PFIZER INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2A7A; MONOCLONAL ANTIBODY MC 3377; TETRASPANIN; TETRASPANIN LIKE PROTEIN TM4SF1; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MEMBRANE ANTIGEN; TM4SF1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL KILLING; CELL MEMBRANE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENDOTHELIUM CELL; GENE EXPRESSION; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RABBIT; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940830090     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0188     Document Type: Article

References (47)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-4.
3. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747-57.
4. Ellis LM, Rosen L, Gordon MS. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 2006;4:suppl 1-10; quz 1-2.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
6. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
7. Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 1986;46:3917-23.
8. Marken JS, Schieven GL, Hellstrom I, Hellstrom KE, Aruffo A. Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci U S A 1992;89:3503-7.
9. Wright MD, Ni J, Rudy GB. The L6 membrane proteins - a new four-transmembrane superfamily. Protein Sci 2000;9:1594-600.
10. Hellstrom I, Beaumier PL, Hellstrom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci U S A 1986;83:7059-63.
11. Shih SC, Zukauskas A, Li D, Liu G, Ang LH, Nagy JA, et al. The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res 2009;69:3272-7.
12. English SB, Shih SC, Ramoni MF, Smith LE, Butte AJ. Use of Bayesian networks to probabilistically model and improve the likelihood of validation of microarray findings by RT-PCR. J Biomed Inform 2009;42:287-95.
13. DeNardo SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, Lamborn KR, et al. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Radiat Appl Instrum B 1991;18:621-31.
14. O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, et al. L6 monoclonal antibody binds prostate cancer. Prostate 1998;37:91-7.
15. Allioli N, Vincent S, Vlaeminck-Guillem V, Decaussin-Petrucci M, Ragage F, Ruffion A, et al. TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration. Prostate 2011;71:1239-50.
16. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, et al. Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res 2003;9:2807-16.
17. Lekishvili T, Fromm E, Mujoomdar M, Berditchevski F. The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility. J Cell Sci 2008;121:685-94.
18. Zukauskas A, Merley A, Li D, Ang LH, Sciuto TE, Salman S, et al. TM4SF1: a tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration. Angiogenesis 2011;14:345-54.
19. Lin CI, Lau CY, Li D, Jaminet SC. Nanopodia-thin, fragile membrane projections with roles in cell movement and intercellular interactions. J Vis Exp 2014:86:e51320.
20. Lin CI, Merley A, Sciuto TE, Li D, Dvorak AM, Melero-Martin JM, et al. TM4SF1: a new vascular therapeutic target in cancer. Angiogenesis 2014;17:897-907.
21. Liu AY, Robinson RR, Hellstrom KE, Murray ED Jr, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A 1987;84:3439-43.
22. Leigh BR, Burke PA, Hong AM, O'Donnell RT, Howell LP, Miers LA, et al. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy. Cancer Biother Radiopharm 1999;14:113-9.
23. DeNardo SJ, Mirick GR, Kroger LA, O'Grady LF, Erickson KL, Yuan A, et al. The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994;73:1023-32.
24. Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995;55:5916s-20s.
25. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaia N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010;10:329-39.
26. Maderna A, Leverett CA. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates. Mol Pharm 2015;12:1798-812.
27. Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem 2014;57:10527-43.
28. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803.
29. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009;15:2594-601.
30. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
31. Fell HP, Gayle MA, Yelton D, Lipsich L, Schieven GL, Marken JS, et al. Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 1992;267:15552-8.
32. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815.
33. Doroski MD, Maderna A, O'Donnell CJ, Subramanyam C, Vetelino BC, Dushin RG, Strop P, Graziani EI, inventors; Pfizer Inc., assignee. Cytotoxic peptides and antibody drug conjugates thereof. United Patent number: W2013072813 A2. 2013May 23.
34. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
35. Shih SC, Smith LE. Quantitative multi-gene transcriptional profiling using real-time PCR with a master template. Exp Mol Pathol 2005;79:14-22.
36. Wada Y, Li D, Merley A, Zukauskas A, Aird WC, Dvorak HF, et al. A multigene transcriptional profiling approach to the discovery of cell signature markers. Cytotechnology 2011;63:25-33.
37. Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993;36:267-73.
38. Seo DC, Sung JM, Cho HJ, Yi H, Seo KH, Choi IS, et al. Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 2007;6:75.
39. Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990;8:1083-92.
40. Thol F, Schlenk RF. Gemtuzumab ozogamicin in acute myeloid leukemia revisited. Expert Opin Biol Ther 2014;14:1185-95.
41. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-41.
42. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36.
43. Reichert JM, Beck A, Lugovskoy AA, Wurch T, Coats S, Brezski RJ. 9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland. mAbs 2014;6:309-26.
44. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013;12:329-32.
45. Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13:1537-48.
46. Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 2013;12:38-47.
47. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.